These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
463 related articles for article (PubMed ID: 36713000)
1. Development of a checklist for the assessment of pharmacovigilance guidelines in Southern Africa: a document review. Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR Ther Adv Drug Saf; 2023; 14():20420986221143272. PubMed ID: 36713000 [TBL] [Abstract][Full Text] [Related]
2. Assessment of pharmacovigilance guidelines in the Southern African Development Community: A document review. Makhene NL; Steyn H; Vorster M; Lubbe MS; Burger JR Pharmacoepidemiol Drug Saf; 2024 Feb; 33(2):e5755. PubMed ID: 38362654 [TBL] [Abstract][Full Text] [Related]
3. The future of Cochrane Neonatal. Soll RF; Ovelman C; McGuire W Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834 [TBL] [Abstract][Full Text] [Related]
4. Effective Pharmacovigilance System Development: EFPIA-IPVG Consensus Recommendations. Peters T; Soanes N; Abbas M; Ahmad J; Delumeau JC; Herrero-Martinez E; Paramananda M; Piper J; Smail-Aoudia F; van der Spuij W; Veizovic T; Winstanley G; Drug Saf; 2021 Jan; 44(1):17-28. PubMed ID: 33289904 [TBL] [Abstract][Full Text] [Related]
5. Outer packaging labelling of medicines in Southern African Development Community (SADC) countries: comparative analysis of requirements and transition terms for harmonisation. Narsai K; Masekela FB; Leufkens HGM; Mantel-Teeuwisse AK BMC Health Serv Res; 2024 Jan; 24(1):111. PubMed ID: 38245720 [TBL] [Abstract][Full Text] [Related]
6. Individual Case Safety Report Replication: An Analysis of Case Reporting Transmission Networks. van Stekelenborg J; Kara V; Haack R; Vogel U; Garg A; Krupp M; Gofman K; Dreyfus B; Hauben M; Bate A Drug Saf; 2023 Jan; 46(1):39-52. PubMed ID: 36565374 [TBL] [Abstract][Full Text] [Related]
7. Harmonization of individual case safety reports transmission requirements among PAHO reference authorities: a review of their current regulation. Lomeli-Silva A; Contreras-Salinas H; Barajas-Virgen MY; Romero-Lopez MS; Rodríguez-Herrera LY Ther Adv Drug Saf; 2024; 15():20420986241228119. PubMed ID: 38323190 [TBL] [Abstract][Full Text] [Related]
8. The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement. Fusaroli M; Salvo F; Begaud B; AlShammari TM; Bate A; Battini V; Brueckner A; Candore G; Carnovale C; Crisafulli S; Cutroneo PM; Dolladille C; Drici MD; Faillie JL; Goldman A; Hauben M; Herdeiro MT; Mahaux O; Manlik K; Montastruc F; Noguchi Y; Norén GN; Noseda R; Onakpoya IJ; Pariente A; Poluzzi E; Salem M; Sartori D; Trinh NTH; Tuccori M; van Hunsel F; van Puijenbroek E; Raschi E; Khouri C Drug Saf; 2024 Jun; 47(6):575-584. PubMed ID: 38713346 [TBL] [Abstract][Full Text] [Related]
9. Adverse Drug Reaction Reporting in Africa and a Comparison of Individual Case Safety Report Characteristics Between Africa and the Rest of the World: Analyses of Spontaneous Reports in VigiBase®. Ampadu HH; Hoekman J; de Bruin ML; Pal SN; Olsson S; Sartori D; Leufkens HG; Dodoo AN Drug Saf; 2016 Apr; 39(4):335-45. PubMed ID: 26754924 [TBL] [Abstract][Full Text] [Related]
10. CIOMS and ICH initiatives in pharmacovigilance and risk management: overview and implications. Tsintis P; La Mache E Drug Saf; 2004; 27(8):509-17. PubMed ID: 15154824 [TBL] [Abstract][Full Text] [Related]
11. Aggregate analysis of regulatory authority assessors' comments to improve the quality of periodic safety update reports. Jullian S; Jaskiewicz L; Pfannkuche HJ; Parker J; Lalande-Luesink I; Lewis DJ; Close P Pharmacoepidemiol Drug Saf; 2015 Sep; 24(9):971-9. PubMed ID: 26175055 [TBL] [Abstract][Full Text] [Related]
12. Comparative Assessment of the National Pharmacovigilance Systems in East Africa: Ethiopia, Kenya, Rwanda and Tanzania. Barry A; Olsson S; Minzi O; Bienvenu E; Makonnen E; Kamuhabwa A; Oluka M; Guantai A; Bergman U; van Puijenbroek E; Gurumurthy P; Aklillu E Drug Saf; 2020 Apr; 43(4):339-350. PubMed ID: 31919794 [TBL] [Abstract][Full Text] [Related]
13. Pharmacovigilance in India, Uganda and South Africa with reference to WHO's minimum requirements. Maigetter K; Pollock AM; Kadam A; Ward K; Weiss MG Int J Health Policy Manag; 2015 Mar; 4(5):295-305. PubMed ID: 25905480 [TBL] [Abstract][Full Text] [Related]
14. Enhancing Pharmacovigilance in Sub-Saharan Africa Through Training and Mentoring: A GSK Pilot Initiative in Malawi. Jusot V; Chimimba F; Dzabala N; Menang O; Cole J; Gardiner G; Ofori-Anyinam O; Oladehin O; Sambakunsi C; Kawaye M; Stegmann JU; Guerra Mendoza Y Drug Saf; 2020 Jun; 43(6):583-593. PubMed ID: 32239447 [TBL] [Abstract][Full Text] [Related]
15. Beyond the black stump: rapid reviews of health research issues affecting regional, rural and remote Australia. Osborne SR; Alston LV; Bolton KA; Whelan J; Reeve E; Wong Shee A; Browne J; Walker T; Versace VL; Allender S; Nichols M; Backholer K; Goodwin N; Lewis S; Dalton H; Prael G; Curtin M; Brooks R; Verdon S; Crockett J; Hodgins G; Walsh S; Lyle DM; Thompson SC; Browne LJ; Knight S; Pit SW; Jones M; Gillam MH; Leach MJ; Gonzalez-Chica DA; Muyambi K; Eshetie T; Tran K; May E; Lieschke G; Parker V; Smith A; Hayes C; Dunlop AJ; Rajappa H; White R; Oakley P; Holliday S Med J Aust; 2020 Dec; 213 Suppl 11():S3-S32.e1. PubMed ID: 33314144 [TBL] [Abstract][Full Text] [Related]
16. Funding and financial sustainability of pharmacovigilance: suggested models for funding pharmacovigilance in resource-limited African countries. Isah AO; Opadeyi AO; Tumwijukye H; Cobelens F; Smith D; Ndomondo-Sigonda M; Harmark L; Tanui P; Tiemersma E; Mmbaga BT; Mahlangu G; Ayinbuomwan SA; Soulaymani R; Pandit JM Ther Adv Drug Saf; 2023; 14():20420986231188836. PubMed ID: 37529763 [TBL] [Abstract][Full Text] [Related]
17. Comparison of Three Regional Medicines Regulatory Harmonisation Initiatives in Africa: Opportunities for Improvement and Alignment. Sithole T; Ngum N; Owusu-Asante M; Walker S; Salek S Int J Health Policy Manag; 2024; 13():8070. PubMed ID: 39099506 [TBL] [Abstract][Full Text] [Related]
18. Pharmacovigilance during the pre-approval phases: an evolving pharmaceutical industry model in response to ICH E2E, CIOMS VI, FDA and EMEA/CHMP risk-management guidelines. Hartford CG; Petchel KS; Mickail H; Perez-Gutthann S; McHale M; Grana JM; Marquez P Drug Saf; 2006; 29(8):657-73. PubMed ID: 16872240 [TBL] [Abstract][Full Text] [Related]
19. What makes joint assessment procedures attractive to the innovative industry: successes, challenges, and proposed improvements. Miletic N; Adam S; Acquah J; Aziz Z; Joos A; Mwangi JM Front Med (Lausanne); 2023; 10():1207954. PubMed ID: 37731723 [TBL] [Abstract][Full Text] [Related]
20. Regulatory Standards and Guidance for the Use of Health Apps for Self-Management in Sub-Saharan Africa: Scoping Review. Bene BA; Ibeneme S; Fadahunsi KP; Harri BI; Ukor N; Mastellos N; Majeed A; Car J J Med Internet Res; 2024 Apr; 26():e49163. PubMed ID: 38602718 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]